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ABSTRACT 
 
Gastric cancer is the second leading cause of cancer death in the world. There is evidence that shows genetic and 
epigenetic change in stomach cancer is as a result of a variety of  oncogenes, tumor suppressor genes,  genes that  
repair the DNA, genes regulating cell cycle and cell adhesion  molecules. P16 is an Inhibitor  of  protein kinase that 
is dependent on Cyclin D. Inactivation of  this gene as a tumor suppressor gene, cause to cancer. This study  was 
conducted to Investigation the P16 hyper-metylation  status  in serum of  gastric cancer patients in Ardabil province 
as the prognostic factor for early diagnosis of gastric cancer. 82 Blood samples of patients with gastric cancer was 
prepared from Aras clinic of Imam Khomeini hospital. After DNA extraction from serum, using methylation-specific 
PCR assay it was examined the existence of  hypermethylation in the P16 gene promoter.  Incidence of free DNA in 
the serum of patients was 59.8%. P16 gene promoter was hyper methylated in 20.4% of subjects. Data analysis 
showed a statistically significant association between P16 methylation status and types of the adenocarcinoma. But 
there was no statistically significant association between methylation status of  P16 with other features (age, sex, 
tumor location).  This study showed P16 gene  methylation of occur in some of gastric cancer patients. This result 
suggests that p16 methylation may be a prognostic marker for early diagnosis of gastric cancer. 
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INTRODUCTION 
 
Gastric cancer is the most common  and second cause of cancer death in the world with very different geographical 
prevalence and this occurred  more than 70 percent of new cases and deaths in developing countries. The highest 
incidence of gastric cancer is in Japan, South America, East Europe and East Asia. In many countries, there is a 
decrease in the overall incidence and mortality of gastric cancer among men and women over the past 75 years. 
However, gastric cancer remains as one of the major killer among cancers [1-6].  
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Aberrant DNA methylation in the promoter region of the gene is leading to inactivation of tumor suppressor genes 
and other genes related to the cancer cells. There is evidence that gastric cancer is a multistep process of genetic and 
epigenetic alterations of several proto-oncogene encodes the protein, tumor suppressor genes, DNA repair genes , 
adhesion molecules and cell cycle regulators. 
 
P16 is inhibitor gene protein kinase dependent on cyclin-D and acts as a tumor suppressor gene. P16 gene is cell 
cycle regulators, which inhibit the function of protein kinase 4 and 6 depending on cyclin-D, causes cell cycle arrest 
at G1 and in this way it is involved in the phosphorylation of retinoblastoma protein [6,10]. Several mechanisms are 
involved in the inactivation of P16 including homozygous deletion, point mutation and the development of CPG 
methylation of the promoter region of the gene to exon 1. In GC, 32-67% of cases inactivation of P16 occurs by 
methylation, whereas homozygous deletions and point mutations have been reported both less than 10%. Therefore, 
methylation of CG is a major mechanism for inactivation of P16.  Inactivation of p16 as tumor suppressor genes 
disrupts the cell cycle regulation mechanisms, and causes facilitation carcinogenesis. It has been reported deletion or 
mutation of p16 in various tumors such as pancreatic cancer [57%], Glicoblastoma [40-70%], esophageal cancer 
[50%] and lung cancer [20%]. The relationship between inactivation of P16 has shown in gastric cancer. 40% of 
gastric cancer is associated with inactivation of P16.  
 
Studies show that gastric adenocarcinoma is the most lethal cancer in Iran that has very difference in death rate in 
various provinces. Based on these studies, Ardabil Province is the highest prevalence of gastric cancer in Iran that is 
the most common cancer. So that 49.1% of men and 25.4% of women are effected with gastric cancer in Ardabil 
province [7, 8]. Therefore this study was designed to assess p16 promoter methylation in serum  samples of gastric 
cancer patients in Ardabil province  
 
MATERIALS AND METHODS 
 
Blood samples from 82 patients with gastric cancer were taken from the Aras clinic of Imam Khomeini Hospital. 
Serum  
 
DNA was extracted using Traizol, chloroform, ethanol 100% and 10% sodium citrate and sodium hydroxideand and 
the Bi-sulfate treatment of DNA was performed using distilled water, soda, hydroquinone, sodium bisulfate, mineral 
oil, isopropanol 80%, glycogen, NH4Ac, ethanol 10 and 70%. Then the using methylation-specific PCR assay it was 
examined the existence of hypermethylation in the P16 gene promoter. For this purpose, it was used in each reaction 
from 5 Mmkcl, Taq DNA polymerase, 20 mM Tris-HCL (pH 8.4), 1.2-2.5 mM MgCl2, 200 mM dNTPS, and 
Mineral oil Destilled deioniz water. Sequencing of Primers used for methylated DNA was F=5΄ 
TTATTAGAGGGTGGGGGGGATCGC3΄ and R=5΄ GACCCCGAACCGCGACCGTAA3΄ and  for non-
methylated DNA was F=5΄TTATTAGAGGGTGGGGTGGATTGT 3' and R=5΄ 
CAACCCCAAACCACAACCATAA3΄.  
 
Samples that were put through PCR processed in the beginning at 95˚C for 5 min, then 35 cycles of 95˚C for 40 sec, 
35 cycles of 64˚ C for 40 sec, 35 cycles of 72˚C for 40 sec, and finally at 72˚C for 10 min. PCR products were 
electrophoresed at 1% agarose gel.  
 
Statistical analysis was performed using SPSS 16 software. The relationship between variables was assessed by χ2 
and Fisher  test and  significant relationship between the variables  was considered P < 0.05  . 
 
RESULTS 
 
Age of gastric cancer patients was 37-86 years and the mean age was 65.5 years with a standard deviation of 1.09. 
72% of patients were male and 28% female;  34.1% of tumors were  diffuse type and 65.9% intestinal type.  
 
The tumors that located on small curvature of the trunk had a higher frequency of the other tumors position and 
frequency of multifocal site with adjacent centers were higher than frequency of multifocal sites with distant center.  
The frequency of serum free DNA in studied patients was 59.8 %. p16 promoter was hyper methylated in 20.4% of 
subjects .  Data analysis indicated a significant association between methylation status of P16 and type of 
adenocarcinoma that shown in Table 1. However, no significant relationship was found between gender and type of 
adenocarcinoma (df = 1, X2 = 0.923, P = 0.337), gender and location of the tumor (p = 0.262), age  group and type 
of adenocarcinoma (p = 0.639), tumor location and type carcinoma (P = 0.345), gender and the presence of free 
DNA (df = 1, X2 = 1.892, P = 0.169), age group and the presence of free DNA (P = 0.399),  type of adenocarcinoma 
and presence of free DNA (df = 1, X2 = 0.363, P = 0.547),  tumor location and presence of free DNA (P = 0.135), 
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gender and methylation status (df = 1, X2 = 0.043, p = 0.835), age group and methylation status (P = 0.418) P16, 
methylation status and tumor location (P = 0.419) P16. 
 
 
Table1. Relationship between methylation statuses of P16 and adenocarcinoma 
 
Methylation status 
Adenocarcinoma  Methylated  Non-methylated  Total 
Diffuse  1  17  18  
Intestinal  9  22  31  
Total  10  39  49  
P=0.049  df =1   X2=3.864  
          
DISCUSSION 
 
There are several methods to suppress the expression of genes in eukaryotes which hyper methylation promoter of 
these genes especially in nucleotide C is one of the most important procedure. Although silencing of these genes 
cause to the cell development and differentiation  But in some cases, aberrant methylation could be disrupted cell 
regulatory systems and sometimes lead to formation of the tumor, association of between hyper methylation in some 
genes and some cancer cell lines and primary tumors had been observed (11, 12, 13, 14, 15). But it is important to 
examine this issue in cell-free DNA released from tumor cells in to the blood stream in some ways. Noninvasive 
assessment of serum or plasma can be detected easily and minimal risk, the risk of cancer and or reveal existence of 
tumors at the early stage and undetectable by the other methods. 
 
Some studies have done related to PI6 promoter gene hypermethylation in the serum of patients with gastric cancer. 
For example, a study conducted in 2002 by Wai Leung et al who it was investigated in samples of tumor tissue and 
serum samples from 54 patients with gastric cancer, the 5 abnormal promoter genes Hypermethylation such as DAP-
Kinase, E-cadherin, GSTP1, P15, P16 MS-PCR method. Promoter methylation of genes) DAP-Kinase70.3%), P16 
(% 66.7), P15 (68.5%), GSTP1 (78.5%), E-cadherin (75.9%) existed in the sample patients and it has been gene 
methylation in serum samples of DAP-Kinase (48.1%), P16 (51.9%), P15 (55.6%), GSTP1 (14.8%), E-cadherin 
(57.4%) and there was no methylation in any of the 30 cases in the control group.  
 
Japanese researchers in 2003 studied, Promoter Hyper methylation of the P16 gene using MS-PCR technique at 
Tumor and serum samples of 60 patients, There is aberrant methylation of P16 in tumor samples of 23 patients 
(38%) of 60 patients, 6 patients out of 23 patients (26%) indicated that changes in serum DNA. In this study, no 
methylation was found in the control group. The findings suggest that DNA methylation of P16 is as a marker for 
tumor detection in serum of patients with gastric cancer.  
 
Another study conducted in 2005 by Livia Huang and colleagues, which has been paid to the study of P16 gene 
promoter hypermethylation in plasma of patients with gastric adenocarcinoma. In this study, tumor tissue and serum 
samples were collected from 84 patients with adenocarcinoma of the stomach before and after surgery. Tumor tissue 
of 26 patients (31%) and two cases of tumor adjacent tissue (0.02%) and plasma of 12 patients (14.3%) before 
surgery show broke hyper methylation of P16, but not in serum, plasma 15 controls hypermethylation of P16.  
 
In 2008, according to a study in Iran on 52 patients with gastric cancer, promoter methylation of P16 is shown in 
44.2% of tumor cells, and 60.9% DNA in the serum of these patients was methylation. But the control group showed 
no methylation in serum and tissues. P16 protein expression in 61.5% of patients has decreased considerably, which 
is associated with hyper methylation of P16. This study has pointed to the possibility of using DNA methylation as a 
biological marker for the early detection of gastric cancer. 
 
According to a study in 2009, the P16 genetic mutation was associated with hereditary melanoma. Removal and 
inactivation of P16 has been reported in 75% of pancreatic cancers, 40 Glico-blastoma 40-70%, esophageal cancer, 
lung cancer 20%. The relationship between the deactivation of P16 has been shown in gastric cancer. 49% of gastric 
adenocarcinoma is associated with inactivation of the P16. 
 
In 2013, South Korean researchers studied the DNA methylation of P16 gene using methylation-specific PCR in 53 
patients with gastric cancer. The P16 gene methylation was detected in 79.2% of  preoperative serum DNA and in 
54.7% of  postoperative serum DNA. P16 methylation patterns did not change after surgery has been reported in 
37.7%, and the appearance of methylation of 13.2%, so that no methylation of P16 after surgery was associated with 
prolonged survival.  
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In the present study, serum markers in patients with gastric cancer were investigated in order to identify markers of 
cancer specialists. Of course, this study exist by the other investigations of genetic markers and epigenetic and most 
importantly, the comparison between the serum of gastric cancer patients and controls for presence of free DNA 
hyper methylation of certain genes, and finally a little comparison of serum free. Due to late diagnosis of the tumor, 
resulting in low patient survival after diagnosis is to find a marker to predict the value of prevention and early 
detection is crucial tumor formation. 
 
Although previous studies have found that significant association between P16 promoter hyper methylation in the 
tumor and tumor samples, however, due to the invasiveness of sampling, is not useful in practice. This causes 
epigenetic issues were addressed in serum as a marker for non-invasive technique helped to detect the disease 
earlier. 
 
This study, like most previous studies, which showed methylation of P16 gene in the percentage of patients with 
gastric cancer and in some cases, a significant correlation was found between hypermethylation and pathologic data 
such as tumor grade. Data analysis revealed a significant association between methylation status and 
adenocarcinomas of the P16. However, the methylation status of P16 with other data (age, sex, tumor location) 
found a statistically significant association. Thus, according to findings in the percentage of patients can be helped 
physicians in the early detection of gastric cancer. According to accompanied studies we can suggest that the 
investigation of quantity of methylation has accompanied in patient serum and the comparison of methylation in 
patient's tumor and serum.  
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